Edgewise Therapeutics Inc (EWTX) - Total Assets
Based on the latest financial reports, Edgewise Therapeutics Inc (EWTX) holds total assets worth $518.52 Million USD as of March 2026. Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments. See EWTX net asset value for net asset value and shareholders' equity analysis.
Edgewise Therapeutics Inc - Total Assets Trend (2019–2025)
This chart illustrates how Edgewise Therapeutics Inc's total assets have evolved over time, based on quarterly financial data.
Edgewise Therapeutics Inc - Asset Composition Analysis
Current Asset Composition (December 2025)
Edgewise Therapeutics Inc's total assets of $518.52 Million consist of 98.3% current assets and 1.7% non-current assets.
| Asset Category | Amount (USD) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | $0.00 | 11.1% |
| Accounts Receivable | $0.00 | 0.0% |
| Inventory | $0.00 | 0.0% |
| Property, Plant & Equipment | $0.00 | 0.0% |
| Intangible Assets | $0.00 | 0.0% |
| Goodwill | $0.00 | 0.0% |
Asset Composition Trend (2019–2025)
This chart illustrates how Edgewise Therapeutics Inc's asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution. For live market cap, price, and company overview, see EWTX market cap.
Key Asset Composition Facts
- Current vs. Non-Current Assets: Edgewise Therapeutics Inc's current assets represent 98.3% of total assets in 2025, an increase from 98.0% in 2019.
- Cash Position: Cash and equivalents constituted 11.1% of total assets in 2025, down from 96.4% in 2019.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 0.0% of total assets, unchanged from 0.0% in 2019.
- Asset Diversification: The largest asset category is goodwill at 0.0% of total assets.
Edgewise Therapeutics Inc Competitors by Total Assets
Key competitors of Edgewise Therapeutics Inc based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
Ligand Pharmaceuticals Incorporated
NASDAQ:LGND
|
USA | $1.53 Billion |
|
Biomarin Pharmaceutical Inc
NASDAQ:BMRN
|
USA | $7.59 Billion |
|
Shanghai Junshi Biosciences Co Ltd
SHG:688180
|
China | CN¥11.69 Billion |
|
Beijing Tiantan Biological Products Corp Ltd
SHG:600161
|
China | CN¥16.55 Billion |
|
Xiamen Amoytop Biotech Co Ltd
SHG:688278
|
China | CN¥3.21 Billion |
|
Tibet Cheezheng Tibetan Medicine Co Ltd
SHE:002287
|
China | CN¥6.66 Billion |
|
Jade Biosciences, Inc.
NASDAQ:JBIO
|
USA | $319.43 Million |
|
Theravance Biopharma Inc
F:0TB
|
Germany | €415.46 Million |
Edgewise Therapeutics Inc - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 22.61 | 20.99 | 44.96 |
| Quick Ratio | 22.61 | 20.99 | 44.96 |
| Cash Ratio | 0.00 | 0.00 | 0.00 |
| Working Capital | $487.25 Million | $422.06 Million | $296.23 Million |
Edgewise Therapeutics Inc - Advanced Valuation Insights
This section examines the relationship between Edgewise Therapeutics Inc's asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | 7.70 |
| Latest Market Cap to Assets Ratio | 6.53 |
| Asset Growth Rate (YoY) | 13.5% |
| Total Assets | $552.60 Million |
| Market Capitalization | $3.61 Billion USD |
Valuation Analysis
Premium Asset Valuation: The market values Edgewise Therapeutics Inc's assets at a significant premium (6.53x), suggesting investors see substantial growth potential or unique competitive advantages.
Rapid Asset Growth: Edgewise Therapeutics Inc's assets grew by 13.5% over the past year, indicating significant expansion of the company's resource base.
Annual Total Assets for Edgewise Therapeutics Inc (2019–2025)
The table below shows the annual total assets of Edgewise Therapeutics Inc from 2019 to 2025.
| Year | Total Assets | Change |
|---|---|---|
| 2025-12-31 | $552.60 Million | +13.51% |
| 2024-12-31 | $486.82 Million | +43.17% |
| 2023-12-31 | $340.04 Million | -7.37% |
| 2022-12-31 | $367.10 Million | +28.70% |
| 2021-12-31 | $285.23 Million | +117.51% |
| 2020-12-31 | $131.14 Million | +434.35% |
| 2019-12-31 | $24.54 Million | -- |
About Edgewise Therapeutics Inc
Edgewise Therapeutics, Inc., a biopharmaceutical company, discovers, develops, and commercializes therapies for the treatment of muscle disorders. Its lead product candidate, sevasemten, an orally administered small molecule that is in Phase II clinical trials, designed to address the root cause of dystrophinopathies including Duchenne muscular dystrophy and Becker muscular dystrophy. The company… Read more